USP28は,糖尿病の心臓におけるミトコンドリアの形態機能障害と心臓機能障害の主要な抑制剤として機能する
Sai-Yang Xie1,2, Shi-Qiang Liu1,2, Tong Zhang1,2
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, P.R. China (S.-y.X, S.-q.L., T.Z., W.-k.S., Y.X., W.-x.F., M.Z., M.-Y.C., L.-l.L., H.Z., N.Z., W.D., Q.z.T.).
Circulation
|November 23, 2023
まとめ
この研究では,ユビキチン特異プロテアゼ28 (USP28) が,PPARαを安定させ,Mfn2を促進することで,糖尿病性心筋病に対する保護作用を示しています. USP28を標的としたUSP28活性化またはAAV治療は,糖尿病性心疾患の有望な治療戦略を提供します.
科学分野:
- 心臓病科
- 代謝 疾患
- 分子生物学
背景:
- 糖尿病性心筋病は 糖尿病の一般的な合併症で 心不全につながります
- 従来の治療法では 糖尿病性心筋病の進行を止めることはできません
- 糖尿病性心筋病の代謝脆弱性におけるUSP28 (ユビキチン特異プロテアゼ28) の役割が調査されました.
研究 の 目的:
- 糖尿病性心筋病におけるUSP28の潜在的役割と治療的価値を評価する.
- 糖尿病患者の心臓におけるUSP28の機能の基礎となる分子メカニズムを解明する.
主な方法:
- 2型糖尿病マウスモデル (db/db,HFD/STZ) と心臓特異のUSP28ノックアウトマウスを使用した.
- 新生ラットの心室筋細胞と人間のiPSC由来心筋細胞を用いたin vitroモデルを使用した.
- RNAシーケンシング,IP/MS,ChIP-seq,およびタンパク質プルダウンアッセイによる分子メカニズムを調査した.
主要な成果:
- 糖尿病の心臓 (マウスと患者) で観察されたUSP28発現の低下
- USP28欠乏は心臓機能障害と脂質蓄積を悪化させ,USP28過剰発現は心臓機能を改善し,線維症を減少させた.
- USP28はPPARαと直接相互作用し,Mfn2転写を促進し,それによってミトコンドリア機能障害を予防しました.
結論:
- USP28は,糖尿病の心臓におけるPPARα-Mfn2軸経由でミトコンドリア・ホメオスタシスを調節する.
- USP28活性化またはAAV媒介USP28治療は,糖尿病性心筋病に対する潜在的な治療戦略です.
関連する概念動画
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626